{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T02:34:00Z","timestamp":1774924440423,"version":"3.50.1"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The optimal dosage and clinical efficacy of vinblastine (VBL) for treatment of mast cell tumors (MCTs) in dogs has not been established.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Hypothesis<\/jats:title>\n                    <jats:p>Single-agent VBL has antitumor activity against MCTs in dogs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Fifty-one dogs with nonresectable grade II or III cutaneous MCTs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Prospective, open clinical trial. Dogs were systematically allocated (by hospital record number) to receive IV treatment with VBL at a dosage of 2.0\u2003mg\/m2 (weekly for 4 treatments then biweekly for 4 treatments; VBL 2.0) or treatment with VBL at a dosage of 3.5\u2003mg\/m2 (biweekly for 5 treatments; VBL 3.5). The primary outcome measure was reduction in tumor size.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-five dogs were allocated to the VBL 2.0 group and 26 were allocated to the VBL 3.5 group. In the VBL 2.0 group, 3 (12%) had a partial response (PR) for a median of 77 days (range, 48\u2013229 days). Overall response rate in the VBL 3.5 group was 27%. One dog (4%) had a complete response for 63 days and 6 dogs (23%) had a PR for a median of 28 days (range, 28\u201378 days). Toxicoses were uncommon in the VBL 2.0 group. Twelve (46%) dogs in the VBL 3.5 group had &amp;lt;500\u2003neutrophils\/\u03bcL 7 days after treatment; 2 dogs with neutropenia developed concurrent fevers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Clinical Importance<\/jats:title>\n                    <jats:p>VBL, when used as a single-agent, has activity against MCTs in dogs although the response rate is lower than those reported for VBL-containing combination protocols. Further, findings suggest VBL at a dosage of 3.5\u2003mg\/m2 should be considered for use in future phase II\/III trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1939-1676.2008.0195.x","type":"journal-article","created":{"date-parts":[[2009,1,22]],"date-time":"2009-01-22T12:15:28Z","timestamp":1232626528000},"page":"1390-1396","source":"Crossref","is-referenced-by-count":38,"title":["Efficacy of Vinblastine for Treatment of Canine Mast Cell Tumors"],"prefix":"10.1093","volume":"22","author":[{"given":"K.M.","family":"Rassnick","sequence":"first","affiliation":[{"name":"College of Veterinary Medicine, Cornell University Department of Clinical Sciences, , Ithaca, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.B.","family":"Bailey","sequence":"additional","affiliation":[{"name":"College of Veterinary Medicine, Cornell University Department of Clinical Sciences, , Ithaca, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.B.","family":"Flory","sequence":"additional","affiliation":[{"name":"College of Veterinary Medicine, Cornell University Department of Clinical Sciences, , Ithaca, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.E.","family":"Balkman","sequence":"additional","affiliation":[{"name":"College of Veterinary Medicine, Cornell University Department of Clinical Sciences, , Ithaca, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.A.","family":"Kiselow","sequence":"additional","affiliation":[{"name":"College of Veterinary Medicine, Cornell University Department of Clinical Sciences, , Ithaca, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.L.","family":"Intile","sequence":"additional","affiliation":[{"name":"College of Veterinary Medicine, Cornell University Department of Clinical Sciences, , Ithaca, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Autio","sequence":"additional","affiliation":[{"name":"College of Veterinary Medicine, Cornell University Department of Clinical Sciences, , Ithaca, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2008,11,1]]},"reference":[{"key":"2026020304255308800_b1","first-page":"585","article-title":"Dose","volume":"69","author":"Frei","year":"1980","journal-title":"A critical factor in cancer chemotherapy"},{"key":"2026020304255308800_b2","first-page":"2027","article-title":"The relationship between high-dose treatment and combination chemotherapy","volume":"4","author":"Frei","year":"1998","journal-title":"The concept of summation dose intensity"},{"key":"2026020304255308800_b3","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1002\/1097-0142(19840915)54:1+<1160::AID-CNCR2820541312>3.0.CO;2-P","article-title":"Increasing the therapeutic response rates to anticancer drugs by applying the basic principles of pharmacology","volume":"54","author":"Schabel","year":"1984","journal-title":"Cancer"},{"key":"2026020304255308800_b4","first-page":"295","volume-title":"Cancer: Principles and Practice of Oncology","author":"Chu","year":"2005","edition":"7th ed"},{"key":"2026020304255308800_b5","first-page":"6806","article-title":"Interaction of vinca alkaloids with tubulin","volume":"35","author":"Lobert","year":"1996","journal-title":"A comparison of vinblastine, vincristine, and vinorelbine"},{"key":"2026020304255308800_b6","first-page":"1320","article-title":"Vinca alkaloids","volume":"29A","author":"Hill","year":"1993","journal-title":"Anti-vascular effects in a murine tumour"},{"key":"2026020304255308800_b7","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1006\/excr.1994.1342","article-title":"Polymerization of tubulin in apoptotic cells is not cell cycle dependent","volume":"215","author":"Pittman","year":"1994","journal-title":"Exp Cell Res"},{"key":"2026020304255308800_b8","first-page":"1015","article-title":"Comparison of the dose- and time survival curves for normal hematopoietic and lymphoma colony-forming cells exposed to vinblastine, vincristine, arabinosylcytosine, and amethopterin","volume":"42","author":"Bruce","year":"1969","journal-title":"J Natl Cancer Inst"},{"key":"2026020304255308800_b9","first-page":"126","volume-title":"Managing the Canine Cancer Patient","author":"Moore","year":"2006"},{"key":"2026020304255308800_b10","first-page":"163","volume-title":"Small Animal Clinical Oncology","author":"Chun","year":"2008","edition":"4th ed"},{"key":"2026020304255308800_b11","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.1939-1676.1999.tb01468.x","article-title":"Prednisone and vinblastine chemotherapy for canine mast cell tumor\u201441 cases (1992\u20131997)","volume":"13","author":"Thamm","year":"1999","journal-title":"J Vet Intern Med"},{"key":"2026020304255308800_b12","doi-asserted-by":"crossref","DOI":"10.1111\/j.1939-1676.2008.0196.x","article-title":"Phase I dose escalation of single-agent vinblastine in dogs","author":"Bailey","year":"2008","journal-title":"J Vet Intern Med"},{"key":"2026020304255308800_b13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"2026020304255308800_b14","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1939-1676.1997.tb00484.x","article-title":"Vincristine therapy for mast cell tumors in dogs","volume":"11","author":"McCaw","year":"1997","journal-title":"J Vet Intern Med"},{"key":"2026020304255308800_b15","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1476-5810.2004.0053b.x","article-title":"Veterinary co-operative oncology group common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0","volume":"2","year":"2004","journal-title":"Vet Compar Oncol"},{"key":"2026020304255308800_b16","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1939-1676.1999.tb02217.x","article-title":"Treatment of canine mast cell tumors with CCNU (lomustine)","volume":"13","author":"Rassnick","year":"1999","journal-title":"J Vet Intern Med"},{"key":"2026020304255308800_b17","first-page":"289","volume-title":"Cancer: Principles and Practice of Oncology","author":"Chu","year":"2001","edition":"6th ed"},{"key":"2026020304255308800_b18","first-page":"1375","article-title":"Randomized phase II clinical trials","volume":"69","author":"Simon","year":"1985","journal-title":"Cancer Treat Rep"},{"key":"2026020304255308800_b19","first-page":"1794","article-title":"Randomized phase II trials","volume":"23","author":"Wieand","year":"2005","journal-title":"What does randomization gain?"},{"key":"2026020304255308800_b20","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1292\/jvms.64.531","article-title":"Immunohistochemical detection of P-glycoprotein (PGP) and multidrug resistance-associated protein (MRP) in canine cutaneous mast cell tumors","volume":"64","author":"Miyoshi","year":"2002","journal-title":"J Vet Med Sci"},{"key":"2026020304255308800_b21","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S0014-5793(98)01663-9","article-title":"Dexamethasone modulation of multidrug transporters in normal tissues","volume":"442","author":"Demeule","year":"1999","journal-title":"FEBS Lett"},{"key":"2026020304255308800_b22","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.2460\/ajvr.68.11.1246","article-title":"Evaluation of a novel immunomodulator composed of human chorionic gonadotropin and bacillus Calmette-Guerin for treatment of canine mast cell tumors in clinically affected dogs","volume":"68","author":"Henry","year":"2007","journal-title":"Am J Vet Res"},{"key":"2026020304255308800_b23","doi-asserted-by":"crossref","first-page":"124","DOI":"10.5326\/0400124","article-title":"Vinblastine and prednisolone as adjunctive therapy for canine cutaneous mast cell tumors","volume":"40","author":"Davies","year":"2004","journal-title":"J Am Anim Hosp Assoc"},{"key":"2026020304255308800_b24","first-page":"156","article-title":"Treatment of canine mast cell tumours with vinblastine, cyclophosphamide and prednisone","volume":"5","author":"Camps-Palau","year":"2007","journal-title":"35 cases (1997\u20132004)"},{"key":"2026020304255308800_b25","first-page":"581","article-title":"Outcome and prognostic factors following adjuvant prednisone\/vinblastine chemotherapy for high-risk canine mast cell tumour","volume":"68","author":"Thamm","year":"2006","journal-title":"61 cases"},{"key":"2026020304255308800_b26","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1200\/JCO.2004.08.176","article-title":"Are chemotherapy response rates related to treatment-induced survival prolongations in patients with advanced cancer?","volume":"22","author":"Shanafelt","year":"2004","journal-title":"J Clin Oncol"},{"key":"2026020304255308800_b27","first-page":"1015","article-title":"Comparison of the dose- and time-survival curves for normal hematopoietic and lymphoma colony-forming cells exposed to vinblastine, vincristine, arabinosylcytosine, and amethopterin","volume":"42","author":"Bruce","year":"1969","journal-title":"J Natl Cancer Inst"},{"key":"2026020304255308800_b28","first-page":"S10","article-title":"Evolving concepts in the systemic drug therapy of breast cancer","volume":"24","author":"Norton","year":"1997","journal-title":"Semin Oncol"},{"key":"2026020304255308800_b29","first-page":"1727","article-title":"A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate","volume":"63","author":"Goldie","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"2026020304255308800_b30","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1476-5829.2007.00135.x","article-title":"Vinblastine and prednisolone chemotherapy for surgically excised grade III canine cutaneous mast cell tumours","volume":"5","author":"Hayes","year":"2007","journal-title":"Vet Compar Oncol"},{"key":"2026020304255308800_b31","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1748-5827.1973.tb06891.x","article-title":"The prognosis following surgical removal of mastocytomas in dogs","volume":"14","author":"Bostock","year":"1973","journal-title":"J Small Anim Pract"},{"key":"2026020304255308800_b32","first-page":"141","article-title":"Prophylactic trimethoprim-sulfadiazine during chemotherapy in dogs with lymphoma and osteosarcoma","volume":"21","author":"Chretin","year":"2007","journal-title":"A double-blind, placebo-controlled study"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1939-1676.2008.0195.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/22\/6\/1390\/66674662\/j.1939-1676.2008.0195.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/22\/6\/1390\/66674662\/j.1939-1676.2008.0195.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T09:26:03Z","timestamp":1770110763000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/22\/6\/1390\/8450094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11,1]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,11,1]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1939-1676.2008.0195.x","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2008,11]]},"published":{"date-parts":[[2008,11,1]]}}}